Top Markets
#1 MarsCoin MarsCoin +48.28%
#2 Palladium Network Palladium Network +27.97%
#3 Siren Siren +27.75%
#4 Status Status +21.38%
#5 Useless Coin Useless Coin +16.56%
#6 BankrCoin BankrCoin +15.25%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +15.16%
#8 Bedrock Bedrock +14.18%
#9 Ankr Network Ankr Network +12.74%
#10 Arweave Arweave +12.66%
Coin of the day
MarsCoin MarsCoin
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Innate Pharma S.A. Innate Pharma S.A.

Innate Pharma S.A.

IPH
Rangering i aksjer #18401
Innate Pharma S.A. is a biotechnology firm dedicated to the discovery,... Innate Pharma S.A. is a biotechnology firm dedicated to the discovery, development, and commercialization of innovative antibody-based therapies, primarily for cancer indications, operating both in France and internationally. The company's pipeline includes several key drug candidates: Lacutamab (IPH4102), an anti-KIR3DL2 antibody, is currently in Phase II clinical trials for treating cutaneous T-cell and peripheral T-cell lymphoma, as well as refractory Sézary syndrome. Monalizumab, an immune checkpoint inhibitor, is undergoing Phase III evaluation for advanced solid tumors, encompassing colorectal, lung, and head and neck cancers. Avdoralimab (IPH5401), a monoclonal antibody designed to block C5a binding to C5aR1, is advancing through Phase II studies for conditions such as COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases. IPH5201, a blocking antibody, is in Phase I clinical trials, aiming to modulate the CD39 immunosuppressive pathway. IPH5301, an anti-CD73 antibody, targets the immunosuppressive adenosine pathway to foster anti-tumor immunity. IPH6101, an NKp46-based NK cell engager, is being developed for the creation and assessment of up to two bispecific NK cell engagers. Beyond clinical stages, their preclinical programs feature IPH43 (an anti-MICA/B antibody drug conjugate), an Anti-Siglec-9 antibody program, IPH65 (a proprietary tetraspecific antibody), IPH25 (a checkpoint inhibitor), along with the IPH62 and IPH64 programs. Innate Pharma S.A. maintains strategic alliances and licensing deals with prominent pharmaceutical entities including AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech, in addition to a co-development and licensing agreement with MedImmune Limited. The company was founded in 1999 and has its headquarters located in Marseille, France.
Aksjekurs
$2.13
Sist synkronisert: 2026-09-02
Markedsverdi
$200.27M
Endring (1 dag)
0.90%
Endring (1 år)
-1.67%
Land
FR
Handel Innate Pharma S.A. (IPH)

Kategori

Healthcare
P/E-forhold for Innate Pharma S.A. (IPH)
P/E-forhold per 2026 TTM: 0
Ifølge Innate Pharma S.A. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for Innate Pharma S.A. fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 31.44 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 36.85 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -17.59 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 -23.32 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.